Gregory Metzger1, Chelsea Horwood1, J C Chen1, Ryan Eaton1, Scott A Strassels2, Robert M Tamer2, Jonathan Wisler3, Heena Santry2, Amy Rushing4. 1. Department of General Surgery, The Ohio State University, Columbus, Ohio. 2. Department of General Surgery, The Ohio State University, Columbus, Ohio; Division of Critical Care, Trauma and Burn, The Ohio State University, Columbus, Ohio; Center for Surgical Health Assessment, Research, and Policy, The Ohio State University, Columbus, Ohio. 3. Department of General Surgery, The Ohio State University, Columbus, Ohio; Division of Critical Care, Trauma and Burn, The Ohio State University, Columbus, Ohio. 4. Department of General Surgery, The Ohio State University, Columbus, Ohio; Division of Critical Care, Trauma and Burn, The Ohio State University, Columbus, Ohio. Electronic address: Amy.Rushing@osumc.edu.
Abstract
BACKGROUND: Cholecystectomy is considered a low-risk procedure with proven safety in many high-risk patient populations. However, the risk of cholecystectomy in patients with active cancer has not been established. METHODS: The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database was queried to identify all patients with disseminated cancer who underwent cholecystectomy from 2005 to 2016. Postcholecystectomy outcomes were defined for patients with cancer and those without by comparing several outcomes measures. A multivariate model was used to estimate the odds of 30-d mortality. RESULTS: We compared outcomes in 3097 patients with disseminated cancer to a matched cohort of patients without cancer. Patients with cancer had more comorbidities at baseline: dyspnea (10.5% versus 7.0%, P < 0.0001), steroid use (10.1% versus 3.0%, P < 0.0001), and loss of >10% body weight in 6-mo prior (9.3% versus 1.6%, P < 0.0001). Patients with cancer sustained higher rates of wound (2.3% versus 5.6%, P < 0.0001), respiratory (1.4% versus 3.9%, P < 0.0001), and cardiovascular (2.0% versus 6.8%, P < 0.0001) complications. In addition, patients with disseminated cancer experienced a longer length of stay and higher 30-d mortality. Multivariate modeling showed that the odds of 30-d mortality was 3.3 times greater in patients with cancer. CONCLUSIONS: Compared to patients without cancer, those with disseminated cancer are at higher risk of complication and mortality following cholecystectomy. Traditional treatment algorithms should be used with caution and care decisions individualized based on the patient's disease status and treatment goals.
BACKGROUND: Cholecystectomy is considered a low-risk procedure with proven safety in many high-risk patient populations. However, the risk of cholecystectomy in patients with active cancer has not been established. METHODS: The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database was queried to identify all patients with disseminated cancer who underwent cholecystectomy from 2005 to 2016. Postcholecystectomy outcomes were defined for patients with cancer and those without by comparing several outcomes measures. A multivariate model was used to estimate the odds of 30-d mortality. RESULTS: We compared outcomes in 3097 patients with disseminated cancer to a matched cohort of patients without cancer. Patients with cancer had more comorbidities at baseline: dyspnea (10.5% versus 7.0%, P < 0.0001), steroid use (10.1% versus 3.0%, P < 0.0001), and loss of >10% body weight in 6-mo prior (9.3% versus 1.6%, P < 0.0001). Patients with cancer sustained higher rates of wound (2.3% versus 5.6%, P < 0.0001), respiratory (1.4% versus 3.9%, P < 0.0001), and cardiovascular (2.0% versus 6.8%, P < 0.0001) complications. In addition, patients with disseminated cancer experienced a longer length of stay and higher 30-d mortality. Multivariate modeling showed that the odds of 30-d mortality was 3.3 times greater in patients with cancer. CONCLUSIONS: Compared to patients without cancer, those with disseminated cancer are at higher risk of complication and mortality following cholecystectomy. Traditional treatment algorithms should be used with caution and care decisions individualized based on the patient's disease status and treatment goals.
Authors: Qi Yan; Jeongsoo Kim; Daniel E Hall; Myrick C Shinall; Katherine Moll Reitz; Karyn B Stitzenberg; Lillian S Kao; Elizabeth L George; Ada Youk; Chen-Pin Wang; Jonathan C Silverstein; Elmer V Bernstam; Paula K Shireman Journal: Ann Surg Date: 2021-06-25 Impact factor: 12.969